

Date: September 30, 2023

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**“Exchange Plaza”, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**To**  
**The General Manager,**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, Phiroz Jeejeebhoy Towers**  
**Dalal Street, Mumbai – 400 001**

**Stock Code: SUVENPHAR**

**Stock Code: 543064**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011 by the promoter of Suven Pharmaceuticals Limited (“Company”).**

.....


We would like to inform you that pursuant to the Share Purchase Agreement dated December 26, 2022 as amended by amendment agreement dated April 21, 2023, executed by and among Berhyanda Limited (“**Acquirer**”), Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust (“**Seller**”) and Mr. Venkateswarlu Jasti (“**Seller Representative**”), the Acquirer has acquired an aggregate of 12,75,37,043 equity shares of the Company from the Seller consisting of 50.10% of the paid up share capital of the Company on a fully diluted basis.

Please find enclosed herewith the disclosure under Regulation 29 (2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011 on behalf of Jasti Property and Equity Holdings Private Limited (in its capacity as sole Trustee of Jasti Family Trust).

We request you to take this document on your record.

Thanking you,  
Yours faithfully,

**For and on behalf of Jasti Property and Equity Holdings Private Limited**  
**(in its capacity as sole Trustee of Jasti Family Trust)**

  
**Venkateswarlu Jasti**  
Plot No. 396, Road No. 22B  
Jubilee Hills, Hyderabad – 500 033  
Telangana, India

**Copy To:**  
The Company Secretary, Suven Pharmaceuticals Limited  
SDE Serene Chambers, 3rd Floor Road No 5, Banjara Hills Hyderabad – 500 034.

**Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company ("TC")	<b>SUVEN PHARMACEUTICALS LIMITED</b>		
Name(s) of the acquirer and Persons Acting in Concert ("PAC") with the acquirer	<b>Jasti Property and Equity Holdings Private Limited (in its capacity as sole Trustee of Jasti Family Trust)</b>		
Whether the acquirer belongs to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition/ disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of:</b>			
a) Shares carrying voting rights	15,27,30,000 <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)			
c) Voting rights ("VR") otherwise than by equity shares			
d) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	15,27,30,000 <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>
<b>Details of acquisition /sale</b>			
a) Shares carrying voting rights acquired/ sold	12,75,37,043 <sup>#</sup>	50.10% <sup>#</sup>	50.10% <sup>#</sup>
b) VRs acquired / sold otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold	0	0%	0%
d) Shares encumbered/ invoked / release by the acquirer	2,51,94,957 <sup>&amp;</sup>	9.90% <sup>&amp;</sup>	9.90% <sup>&amp;</sup>
e) Total (a+b+c+/-d)	15,27,30,000 <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>

<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights acquired	12,75,37,043 <sup>#</sup>	50.10% <sup>#</sup>	50.10% <sup>#</sup>
b) Shares encumbered with the acquirer	2,51,94,957 <sup>&amp;</sup>	9.90% <sup>&amp;</sup>	9.90% <sup>&amp;</sup>
c) VRs otherwise than by shares	0	0%	0%
d) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
e) Total (a+b+c+d)	15,27,30,000 <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>	60.00% <sup>#&amp;</sup>
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Sale by way of an “off-market” <sup>&amp;</sup> .		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	September 29, 2023		
Equity share capital / total voting capital of the TC before the said acquisition / sale	25,45,64,956 equity shares of the TC		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	25,45,64,956 equity shares of the TC		
Total diluted share/voting capital of the TC after the said acquisition	25,45,64,956 equity shares of the TC		

<sup>#</sup> The Acquirer has triggered a mandatory open offer in compliance with Regulations 3(1) and 4 and other applicable regulations of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“**Takeover Regulations**”), pursuant to the execution of the SPA (as defined in <sup>&</sup> below) to acquire more than 25% of the equity share capital of the Target Company and control over the Target Company. In this regard, the Acquirer has initiated the process for the open offer and has issued a public announcement on 26 December 2022, published the detailed public statement on 2 January 2023 and submitted a draft letter of offer with the Securities and Exchange Board of India on 9 January 2023, in accordance with the applicable provisions of the Takeover Regulations. The Acquirer has acquired 12,75,37,043 equity shares of the Target Company in compliance with Regulation 22(2) of the Takeover Regulations.

& In terms of the share purchase agreement dated 26 December 2022, as amended by amendment agreement dated April 21, 2023, (“SPA”) entered into between Berhyanda Limited (as Acquirer) (“Acquirer”), Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust) (“Seller”) and Mr. Venkateswarlu Jasti (“Seller Representative”), on and from consummation of the SPA (in terms of and subject to the SPA), and for a period of 18 months thereafter, the Seller and/or the Seller Representative shall not, without the prior written consent of the Acquirer, sell or otherwise encumber any equity shares of the TC held by them in favour of any person. As on the date of making this disclosure, the Seller and Seller Representative hold 2,51,92,957 (9.90%) and 2,000 (0%) equity shares in the TC respectively after the sale of 12,75,37,043 equity shares to the Acquirer pursuant to the SPA.

**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the Listing Agreement (i.e., presently the filing done under Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as of 30 June 2023).

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**For and on behalf of Jasti Property and  
Equity Holdings Private Limited (in its  
capacity as sole Trustee of Jasti Family Trust)** )



---

**Authorised Signatory**

Name: Venkateswarlu Jasti

Designation: Director

Date: September 30, 2023

Place: Hyderabad